



November 2, 2017

## CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in three upcoming investor conferences.

### **Craig-Hallum Alpha Select Conference** in New York City

- | Peter Maag will present on Thursday, November 16<sup>th</sup> at 5:40 am PT/8:40 am ET

### **29<sup>th</sup> Annual Piper Jaffray Healthcare Conference** in New York City

- | Peter Maag will present on Tuesday, November 28<sup>th</sup> at 11:30 am PT/2:30 pm ET

### **Global Mizuho Investor Conference** in New York City

- | Peter Maag and Michael Bell will host investor meetings on Monday and Tuesday, December 4<sup>th</sup> and 5<sup>th</sup>.

Live audio webcasts of the Craig-Hallum Alpha Select Conference and the 29<sup>th</sup> Annual Piper Jaffray Healthcare Conference will be available online from the investor relations section of the CareDx website at <http://investors.caredxinc.com/>. The webcast replay of the presentation will be available approximately one hour following the conclusion of the live presentation and will be available on the Company's website for 90 days. Due to the one-on-one only format of the Global Mizuho Investor Conferences, no webcast will be available for this event.

### **About CareDx**

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: [www.CareDx.com](http://www.CareDx.com).

### **CONTACTS:**

CareDx, Inc.  
Sasha King  
Chief Commercial Officer  
415-287-2393  
[sking@caredx.com](mailto:sking@caredx.com)

Investor Relations  
David Clair  
Integrated Corporate Relations, Inc.  
646-277-1266  
[david.clair@icrinc.com](mailto:david.clair@icrinc.com)

Source: CareDx, Inc.

News Provided by Acquire Media